Health Condition 1: F419- Anxiety disorder, unspecified Health Condition 2: F449- Dissociative and conversion disorder, unspecified Health Condition 3: F509- Eating disorder, unspecified Health Condition 4: F339- Major depressive disorder, recurrent, unspecified Health Condition 5: F329- Major depressive disorder, singleepisode, unspecified Health Condition 6: F489- Nonpsychotic mental disorder, unspecified Health Condition 7: F429- Obsessive-compulsive disorder, unspecified Health Condition 8:
Conditions
Interventions
Intervention1: NIL: NIL
Control Intervention1: NIL: NIL
Sponsors
All India Institute of Medical Sciences Raipur Chhattisgarh
Eligibility
Inclusion criteria
Inclusion criteria: 1) Newly diagnosed patients of Depression/ Anxiety/ OCD/ Somatoform disorder who will be started on SSRI therapy 2) Those who will consent to participate
Exclusion criteria
Exclusion criteria: 1) History of anti-psychotic treatment (olanzapine, quetiapine, ziprasidone, risperidone, aripiprazole) 2) History of substance abuse (amphetamines, cocaine, ecstasy) 3) Pregnant women 4) History of use of drugs which either increase body weight/ BMI/ promote atherosclerosis (TCAs, OCPs, MAOIs, Corticosteroids, Anti-epileptics) 5) Any patient who is concurrently using statins 6) Any patient with depression following cerebrovascular accident 7) Any patient with Thyroid disease/ newly diagnosed with thyroid disease 8) Any patient with dyslipidemia 9) Any patient with BMI of overweight (25.0-29.9) or obese (>= 30.0)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of patients with at least 5% increase in total cholesterol level from baselineTimepoint: First Visit (Baseline, 0 weeks) Second Visit (12th week) Third Visit (24th week) | — |
Secondary
| Measure | Time frame |
|---|---|
| Number of patients showing increase in BMI, waist circumference, waist hip ratio and CRP, and irregularities in ECG from the baseline at the end of six-month follow-up.Timepoint: First Visit (Baseline, 0 weeks) Second Visit (12th week) Third Visit (24th week);Number of patients showing increased Apolipoprotein B100 from the baseline at the end of six-month follow-up.Timepoint: First Visit (Baseline, 0 weeks) Third Visit (24th week) | — |
Countries
India
Contacts
Public ContactDr Dhyuti Gupta
All India Institute of Medical Sciences
Outcome results
None listed